Cyclophilin Inhibition as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH)

Expert Opinion on Investigational Drugs - United Kingdom
doi 10.1080/13543784.2020.1703948
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

A New Method to Induce Nonalcoholic Steatohepatitis (NASH) in Mice

BMC Gastroenterology
MedicineGastroenterology
2019English

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma

Canadian Journal of Gastroenterology and Hepatology
MedicineHepatologyGastroenterology
2018English

Letter: Clinical Response to Pioglitazone in Nonalcoholic Steatohepatitis [NASH] Treatment-Use of Pharmacokinetic Surrogate

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Gp78, an E3 Ubiquitin Ligase Acts as a Gatekeeper Suppressing Nonalcoholic Steatohepatitis (NASH) and Liver Cancer

PLoS ONE
Multidisciplinary
2015English

A New Mechanism of Lipotoxicity: Calcium Channel Blockers as a Treatment for Nonalcoholic Steatohepatitis?

Hepatology
MedicineHepatology
2015English

Mouse Models of Nonalcoholic Steatohepatitis Towards Optimization of Their Relevance to Human NASH

Hepatology
MedicineHepatology
2019English

Nonalcoholic Steatohepatitis

English

Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Clinics in Liver Disease
Hepatology
2018English

C-Met Signaling Protects From Nonalcoholic Steatohepatitis- (NASH-) Induced Fibrosis in Different Liver Cell Types

Oxidative Medicine and Cellular Longevity
BiochemistryMedicineCell BiologyAging
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy